Switzerland Mental health is a global crisis. 25 percent of the world’s population struggle with mental illness; and mental, neurological, and substance use disorders account for 11 percent of the total global disease burden according to data from the Healthy Brains Global Initiative (HBGI). Global mental healthcare costs are expected to…
Switzerland This article forms part of Healthcare & Life Sciences Review: Switzerland February 2021, a comprehensive up-to-date country report on the Swiss pharma market, featuring data snapshots, feature articles, exclusive interviews and more. Click here to download. Long heralded as an innovation powerhouse able to hold its own against the…
Switzerland As part of the Federal Department of Home Affairs, the Federal Office of Public Health (FOPH) is responsible for public health in Switzerland; developing the country’s health policy and working to create an efficient and affordable healthcare system in the long term. PharmaBoardroom recently sat down with the FOPH’s newly…
Switzerland Switzerland, rightly regarded as one of the world’s most innovative nations, risks damaging its reputation if innovative new medicines continue to face significant delays and roadblocks in their introduction to the domestic Swiss market. Key stakeholders from pharma industry associations Interpharma and scienceindustries and local affiliate heads for multinationals Bayer…
See our Cookie Privacy Policy Here
